STOCK TITAN

DENTSPLY SIRONA (XRAY) SEC Filings

XRAY NASDAQ

DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.

The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.

Rhea-AI Summary

Fuller & Thaler Asset Management, Inc. reported beneficial ownership of 9,774,111 shares of DENTSPLY SIRONA Inc. common stock, equal to 4.90% of the class, as of September 30, 2026. It reported sole voting power over 9,759,461 shares and sole dispositive power over 9,774,111 shares, with no shared voting or dispositive power.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
ownership
-
Rhea-AI Summary

DENTSPLY SIRONA Inc. (XRAY) VP, Chief Accounting Officer Kevin Czerney had 2,273 shares withheld on November 11, 2026, to cover taxes related to vesting of previously reported restricted stock units and dividend equivalent units. He directly held 39,550 shares after the transaction. That reported balance includes 554 shares acquired under the Dentsply Sirona Employee Stock Purchase Plan between January 1 and June 30, 2026; no Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
insider
-
Rhea-AI Summary

DENTSPLY SIRONA Inc. (XRAY) SVP, GC & Secretary Lindi Rene Barton-Brobst had 1,704 shares withheld on November 11, 2026, to cover taxes related to vesting of previously reported Restricted Stock Units and dividend equivalent units. Her reported direct holdings afterward were 43,482 shares; a separate 255-share holding was held indirectly through a 401(k).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
insider
Rhea-AI Summary

DENTSPLY SIRONA Inc. (XRAY) reported third-quarter 2026 net sales of $836 million, compared with $904 million a year earlier. Net loss attributable to the company was $2 million, versus a $427 million loss; for the first nine months, sales were $2.614 billion versus $2.719 billion and attributable net income was $25 million versus a $452 million loss.

Nine-month operating cash flow was $171 million, versus $134 million. An intercompany inventory estimate revision increased net income approximately $30 million, or $0.15 per basic and diluted share, for the three- and nine-month periods ended September 30, 2026; equivalent impacts are not expected in future periods. The 2026 restructuring plan is expected to carry approximately $60 million to $65 million in total non-recurring charges, the majority expensed and paid in cash in 2026 and 2027.

DENTSPLY SIRONA entered debt amendments on October 8, 2026, increasing maximum permitted leverage ratios, allowing additional EBITDA adjustments for the September and December 2026 quarters, and temporarily restricting certain new liens, subsidiary debt and restricted payments subject to exceptions; fees were approximately $4 million. For a proposed settlement subject to court approval, it recorded a $75 million liability and offsetting insurance receivable; insurers are to fund it, with no income-statement impact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.24%
Tags
quarterly report
-
Rhea-AI Summary

DENTSPLY SIRONA Inc. reported third-quarter 2026 net sales of $836 million, down 7.6% from $904 million a year earlier. Its GAAP gross margin was 52.9%, versus 48.8% in Q3 2025; the GAAP net loss attributable to the company was $2 million, compared with a $427 million loss. Adjusted EBITDA was $146 million, down 13.3%, and its margin was 17.3% versus 18.4%; adjusted EPS was $0.29 versus $0.42 in Q3 2025.

Gross profit and adjusted EBITDA included a $39 million benefit from refining the estimate used to eliminate unrealized profit in inventory. The adjustment reduced reported net loss and increased adjusted net income by approximately $30 million; equivalent impacts are not expected in future. Operating cash flow was $32 million versus $79 million, and free cash flow was $0 million versus $40 million. Cash and cash equivalents were $195 million as of September 30, 2026.

For 2026, the company updated its outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30, excluding the $0.17 one-time benefit from tariff refunds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.24%
Tags
current report
-
Rhea-AI Summary

DENTSPLY SIRONA Inc. obtained consent from the requisite lenders under its revolving credit facility and entered into a credit-agreement amendment and three note-purchase amendments. The amendments increase the maximum permitted Total Leverage Ratio and Senior Leverage Ratio for the fiscal quarters ending September 30 and December 31, 2026, and permit an additional EBITDA addback for certain cash charges or expenses incurred in those quarters.

Until delivery of a compliance certificate for the fiscal year ending December 31, 2026, the amendments generally prohibit new liens and new subsidiary debt, except for those existing before September 30, 2026, and limit restricted payments, with carveouts. During a specified period, they also add quarterly reporting on certain initiatives and related costs and savings.

The credit amendment adds a pricing level for the applicable margin and facility fee. The note amendments increase incremental interest payable if the Company’s total leverage ratio equals or exceeds specified thresholds. DENTSPLY SIRONA said the revised terms are intended to allow it to maintain compliance with its debt covenants in all material respects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.40%
Tags
current report
Rhea-AI Summary

DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky acquired 3,323 phantom stock units on September 30, 2026, at a reported $9.03 per share. Each phantom share is economically equivalent to one common share, and his reported direct phantom-stock balance after the award was 23,345 units. The units become payable in common stock following termination of his service as a director.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
insider
-
Rhea-AI Summary

Southpoint Master Fund and affiliated entities, together with John S. Clark II, report beneficial ownership of 7,000,000 shares of Dentsply Sirona Inc. common stock. This represents 3.5% of the common stock, based on 199,353,876 shares outstanding as of July 24, 2026. The shares are held by Southpoint Master Fund, LP, with Southpoint Capital Advisors LP as investment manager and Southpoint GP, LP as general partner, and related general partner entities and Mr. Clark reported as having shared voting and dispositive power. Each reporting person disclaims beneficial ownership beyond its or his pecuniary interest. The filing states that the group owns 5 percent or less of the class.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
ownership
-
Rhea-AI Summary

AQR Capital Management, LLC and its parent AQR Capital Management Holdings, LLC report beneficial ownership of 10,458,771 shares of DENTSPLY SIRONA Inc. common stock on a Schedule 13G. This position represents 5.22% of the outstanding common stock. Both entities report shared voting and shared dispositive power over all 10,458,771 shares, with no sole voting or sole dispositive power reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
ownership
Rhea-AI Summary

DENTSPLY SIRONA Inc. EVP & CFO John C. Fortson reported equity awards. He received 24,014 shares of Common Stock in the form of Restricted Stock Units that vest in one-third annual installments over three years ending August 10, 2029. He was also granted 104,200 stock options to buy Common Stock at an exercise price of $12.83 per share, vesting in similar one-third annual increments through August 10, 2029, and expiring on August 10, 2036.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
insider

FAQ

How many DENTSPLY SIRONA (XRAY) SEC filings are available on StockTitan?

StockTitan tracks 147 SEC filings for DENTSPLY SIRONA (XRAY), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for DENTSPLY SIRONA (XRAY)?

The most recent SEC filing for DENTSPLY SIRONA (XRAY) was filed on November 16, 2026.